1
|
Zhang Y, Abdollahi A, Andolino C, Tomoo K, Foster BM, Aryal UK, Henderson GC. Performance evaluation of different albumin assays for the detection of analbuminemia. PLoS One 2024; 19:e0300130. [PMID: 38446837 PMCID: PMC10917273 DOI: 10.1371/journal.pone.0300130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2023] [Accepted: 02/21/2024] [Indexed: 03/08/2024] Open
Abstract
Analbuminemia is characterized by the near absence of albumin in the plasma. Different methods are available for measuring albumin levels, but they do not necessarily agree with one another. It is a concern that analbuminemic samples could be falsely characterized due to the incorrect estimation of albumin. The objective of the work was to evaluate the performance of different assays in detecting analbuminemia. Albumin knockout (Alb-/-) mouse plasma was used to test the suitability of different albumin assays for their ability to properly characterize extreme albumin deficiency. Bromocresol green (BCG), bromocresol purple (BCP), enzyme-linked immunosorbent assay (ELISA), liquid chromatography-tandem mass spectrometry (LC-MS/MS), and gel electrophoresis were tested. The LC-MS/MS assay exhibited broad coverage of the amino acid sequence of albumin and indicated 8,400-fold lower (P<0.0001) albumin expression in Alb-/- than wildtype (WT), demonstrating its suitability for identifying extreme albumin deficiency. ELISA estimated albumin at 1.5±0.1 g/dL in WT and was below the detection limit in all Alb-/- samples. Gel electrophoresis yielded consistent results with LC-MS/MS and ELISA. The BCG assay overestimated albumin with apparently appreciable albumin concentrations in Alb-/- mice, yet the assay still indicated a significant difference between genotypes (Alb-/-, 1.2±0.05 g/dL, WT, 3.7±0.1 g/dL, P<0.0001). BCP drastically overestimated albumin and could not successfully identify the known analbuminemic phenotype of Alb-/- mice. By using Alb-/- plasma as a reference material and LC-MS/MS as a reference method, ELISA and gel electrophoresis appear appropriate for identifying analbuminemia, while BCG and BCP are not suitable. It is concluded that dye-binding assays should be avoided when extreme hypoalbuminemia or analbuminemia is suspected.
Collapse
Affiliation(s)
- Yi Zhang
- Department of Nutrition Science, Purdue University, West Lafayette, IN, United States of America
| | - Afsoun Abdollahi
- Department of Nutrition Science, Purdue University, West Lafayette, IN, United States of America
| | - Chaylen Andolino
- Purdue Proteomics Facility, Purdue University, West Lafayette, IN, United States of America
| | - Keigo Tomoo
- Department of Nutrition Science, Purdue University, West Lafayette, IN, United States of America
| | - Bailey M. Foster
- Department of Nutrition Science, Purdue University, West Lafayette, IN, United States of America
| | - Uma K. Aryal
- Purdue Proteomics Facility, Purdue University, West Lafayette, IN, United States of America
- Department of Comparative Pathobiology, Purdue University, West Lafayette, IN, United States of America
| | - Gregory C. Henderson
- Department of Nutrition Science, Purdue University, West Lafayette, IN, United States of America
| |
Collapse
|
2
|
Alterations in the Plasma Protein Expression Pattern in Congenital Analbuminemia—A Systematic Review. Biomolecules 2023; 13:biom13030407. [PMID: 36979342 PMCID: PMC10046341 DOI: 10.3390/biom13030407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Revised: 02/07/2023] [Accepted: 02/11/2023] [Indexed: 02/25/2023] Open
Abstract
Albumin is a highly abundant plasma protein with multiple functions, including the balance of fluid between body compartments and fatty acid trafficking. Humans with congenital analbuminemia (CAA) do not express albumin due to homozygosity for albumin gene mutation. Lessons about physiological control could be learned from CAA. Remarkably, these patients exhibit an apparently normal lifespan, without substantial impairments in physical functionality. There was speculation that tolerance to albumin deficiency would be characterized by significant upregulation of other plasma proteins to compensate for analbuminemia. It is unknown but possible that changes in plasma protein expression observed in CAA are required for the well-documented survival and general wellness. A systematic review of published case reports was performed to assess plasma protein pattern remodeling in CAA patients who were free of other illnesses that would confound interpretation. From a literature search in Pubmed, Scopus, and Purdue Libraries (updated October 2022), concentration of individual plasma proteins and protein classes were assessed. Total plasma protein concentration was below the reference range in the vast majority of CAA patients in the analysis, as upregulation of other proteins was not sufficient to prevent the decline of total plasma protein when albumin was absent. Nonetheless, an impressive level of evidence in the literature indicated upregulated plasma levels of multiple globulin classes and various specific proteins which may have metabolic functions in common with albumin. The potential role of this altered plasma protein expression pattern in CAA is discussed, and the findings may have implications for other populations with hypoalbuminemia.
Collapse
|
3
|
Minchiotti L, Caridi G, Campagnoli M, Lugani F, Galliano M, Kragh-Hansen U. Diagnosis, Phenotype, and Molecular Genetics of Congenital Analbuminemia. Front Genet 2019; 10:336. [PMID: 31057599 PMCID: PMC6478806 DOI: 10.3389/fgene.2019.00336] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Accepted: 03/29/2019] [Indexed: 12/25/2022] Open
Abstract
Congenital analbuminemia (CAA) is an inherited, autosomal recessive disorder with an incidence of 1:1,000,000 live birth. Affected individuals have a strongly decreased concentration, or complete absence, of serum albumin. The trait is usually detected by serum protein electrophoresis and immunochemistry techniques. However, due to the existence of other conditions in which the albumin concentrations are very low or null, analysis of the albumin (ALB) gene is necessary for the molecular diagnosis. CAA can lead to serious consequences in the prenatal period, because it can cause miscarriages and preterm birth, which often is due to oligohydramnios and placental abnormalities. Neonatally and in early childhood the trait is a risk factor that can lead to death, mainly from fluid retention and infections in the lower respiratory tract. By contrast, CAA is better tolerated in adulthood. Clinically, in addition to the low level of albumin, the patients almost always have hyperlipidemia, but they usually also have mild oedema, reduced blood pressure and fatigue. The fairly mild symptoms in adulthood are due to compensatory increment of other plasma proteins. The condition is rare; clinically, only about 90 cases have been detected worldwide. Among these, 53 have been studied by sequence analysis of the ALB gene, allowing the identification of 27 different loss of function (LoF) pathogenic variants. These include a variant in the start codon, frame-shift/insertions, frame-shift/deletions, nonsense variants, and variants affecting splicing. Most are unique, peculiar for each affected family, but one, a frame-shift deletion called Kayseri, has been found to cause about one third of the known cases allowing to presume a founder effect. This review provides an overview of the literature about CAA, about supportive and additional physiological and pharmacological information obtained from albumin-deficient mouse and rat models and a complete and up-to-date dataset of the pathogenic variants identified in the ALB gene.
Collapse
Affiliation(s)
| | - Gianluca Caridi
- Laboratory of Molecular Nephrology, Istituto Giannina Gaslini (IRCCS), Genoa, Italy
| | | | - Francesca Lugani
- Laboratory of Molecular Nephrology, Istituto Giannina Gaslini (IRCCS), Genoa, Italy
| | - Monica Galliano
- Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | | |
Collapse
|
4
|
Suppressa P, Carbonara C, Lugani F, Campagnoli M, Troiano T, Minchiotti L, Sabbà C. Congenital analbuminemia in a patient affected by hypercholesterolemia: A case report. World J Clin Cases 2019; 7:466-472. [PMID: 30842957 PMCID: PMC6397822 DOI: 10.12998/wjcc.v7.i4.466] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/17/2018] [Revised: 12/07/2018] [Accepted: 12/12/2018] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Congenital analbuminemia (CAA) is a very rare disorder. Our data describes the clinical features and laboratory results of a new case established by mutation analysis of the albumin gene in a 39-year-old woman presenting with hypercholesterolemia. Our findings contribute to shed light on the molecular genetics of the disorder and confirm that safe and well tolerated hypocholesterolemic treatment with atorvastatin may be administered in dislipidemic patient with CAA in order to reduce their cardiovascular risk.
CASE SUMMARY Our patient presented with a history of hypercholesterolemia and referred asthenia and heaviness in both legs. She was born from healthy and non-consanguineous parents and her development was normal. She had not familiarity for early cardiovascular disease, and did not report personal history of hypertension, chronic kidney or liver diseases. Clinical laboratories results showed critically reduced value of albumin whereas other serum proteins were elevated. Main causes of hypoalbuminemia (proteinuria, inflammatory state and insufficient hepatic synthesis) were ruled out by normal procedures and laboratory tests. So the hypothesis of a CAA was tested through mutation analysis of the albumin gene that revealed a homozygous CA deletion in exon 12, at nucleotide positions c1614-1615. This finding brought to the diagnosis of CAA. Currently the patient receives Atorvastatin 20 mg od and undergoes clinical and laboratory follow-up every six months. She never needed albumin infusions.
CONCLUSION Our experience shows how treatment with atorvastatin may be safely administered and well tolerated in patients affected by CAA.
Collapse
Affiliation(s)
- Patrizia Suppressa
- Department of Internal Medicine and Rare Disease Centre, University Hospital of Bari, Bari 70124, Italy
| | - Concetta Carbonara
- Department of Medicine, University of Bari, School of Medicine, Bari 70124, Italy
| | - Francesca Lugani
- Laboratory of Molecular Nephrology, Istituto Giannini Gaslini, IRCCS, Genova 16148, Italy
| | - Monica Campagnoli
- Department of Molecular Medicine, University of Pavia, Pavia 27100, Italy
| | - Teresa Troiano
- Department of Clinical Pathology, University Hospital of Bari, Bari 70124, Italy
| | - Lorenzo Minchiotti
- Department of Molecular Medicine, University of Pavia, Pavia 27100, Italy
| | - Carlo Sabbà
- Department of Interdisciplinary Medicine, Geriatric Unit and Rare Disease Center, "Aldo Moro" University, Bari 70125, Italy
| |
Collapse
|
5
|
Chen Y, Yu Q, Huang Z, Wang B, Xu Q, Lan L, Chang G, Zhang Y, Chen G. Specific expression and promoter analysis of the albumin gene promoter of the duck (Anas platyrhynchos domesticus). Br Poult Sci 2017; 58:19-25. [DOI: 10.1080/00071668.2016.1236361] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Y. Chen
- The Key Laboratory of Animal Genetics & Breeding and Molecular Design of Jiangsu Province, Yangzhou University, Yangzhou, P.R. China
| | - Q. Yu
- College of Animal Science and Technology, Jiangxi Agricultural University, Jiangxi, P.R. China
| | - Z. Huang
- The Key Laboratory of Animal Genetics & Breeding and Molecular Design of Jiangsu Province, Yangzhou University, Yangzhou, P.R. China
| | - B. Wang
- The Key Laboratory of Animal Genetics & Breeding and Molecular Design of Jiangsu Province, Yangzhou University, Yangzhou, P.R. China
| | - Q. Xu
- The Key Laboratory of Animal Genetics & Breeding and Molecular Design of Jiangsu Province, Yangzhou University, Yangzhou, P.R. China
| | - L. Lan
- College of Animal Science and Technology, Jiangxi Agricultural University, Jiangxi, P.R. China
| | - G. Chang
- The Key Laboratory of Animal Genetics & Breeding and Molecular Design of Jiangsu Province, Yangzhou University, Yangzhou, P.R. China
| | - Y. Zhang
- The Key Laboratory of Animal Genetics & Breeding and Molecular Design of Jiangsu Province, Yangzhou University, Yangzhou, P.R. China
| | - G. Chen
- The Key Laboratory of Animal Genetics & Breeding and Molecular Design of Jiangsu Province, Yangzhou University, Yangzhou, P.R. China
| |
Collapse
|
6
|
Caridi G, Gulec EY, Campagnoli M, Lugani F, Onal H, Kilic D, Galliano M, Minchiotti L. A nucleotide deletion and frame-shift cause analbuminemia in a Turkish family. Biochem Med (Zagreb) 2016; 26:264-71. [PMID: 27346974 PMCID: PMC4910280 DOI: 10.11613/bm.2016.031] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Accepted: 04/13/2016] [Indexed: 12/25/2022] Open
Abstract
Congenital analbuminemia is an autosomal recessive disorder, in which albumin, the major blood protein, is present only in a minute amount. The condition is a rare allelic heterogeneous defect, only about seventy cases have been reported worldwide. To date, more than twenty different mutations within the albumin gene have been found to cause the trait. In our continuing study of the molecular genetics of congenital analbuminemia, we report here the clinical and biochemical findings and the mutation analysis of the gene in two Turkish infants. For the molecular analysis, we used our strategy, based on the screening of the gene by single-strand conformation polymorphism, heteroduplex analysis and direct DNA sequencing. The results showed that both patients are homozygous for the deletion of a cytosine residue in exon 5, in a stretch of four cytosines starting from nucleotide position 524 and ending at position 527 (NM_000477.5(ALB):c.527delC). The subsequent frame-shift inserts a stop codon in position 215, markedly reducing the size of the predicted protein product. The parents are both heterozygous for the same mutation, for which we propose the name Erzurum from the city of origin of the family. In conclusion, our results show that in this family congenital analbuminemia is caused by a novel frame-shift/deletion defect, confirm the inheritance of the trait, and contribute to advance our understanding of the molecular basis underlying this condition.
Collapse
Affiliation(s)
- Gianluca Caridi
- Laboratory on Pathophysiology of Uremia, Istituto Giannina Gaslini IRCCS, Genova, Italy
| | - Elif Yilmaz Gulec
- Department of Medical Genetics, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey
| | | | - Francesca Lugani
- Laboratory on Pathophysiology of Uremia, Istituto Giannina Gaslini IRCCS, Genova, Italy
| | - Hasan Onal
- Department of Pediatric Metabolism and Nutrition, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey
| | - Duzgun Kilic
- Department of Biochemistry, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey
| | - Monica Galliano
- Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | | |
Collapse
|
7
|
Minchiotti L, Galliano M, Caridi G, Kragh-Hansen U, Peters T. Congenital analbuminaemia: molecular defects and biochemical and clinical aspects. Biochim Biophys Acta Gen Subj 2013; 1830:5494-502. [PMID: 23612153 DOI: 10.1016/j.bbagen.2013.04.019] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2013] [Revised: 04/11/2013] [Accepted: 04/15/2013] [Indexed: 12/25/2022]
Abstract
BACKGROUND DNA and mRNA sequencing of the coding regions of the human albumin gene (ALB) and of its intron/exon junctions has revealed twenty-one different molecular defects causing congenital analbuminaemia (CAA). SCOPE OF REVIEW To describe the mutations in molecular terms and to present the current knowledge about the most important biochemical and clinical effects of CAA. MAJOR CONCLUSIONS CAA is rare, but its frequency seems to be significantly higher in restricted and minimally admixed populations. The condition affects especially the lipid metabolism but apart from a possible increased risk for atherosclerotic complications, it is generally associated with mild clinical symptoms in adults. By contrast, several reports indicate that analbuminaemic individuals may be at risk during the perinatal and childhood periods, in which they seem to show increased morbidity and mortality. The twenty-one causative defects include seven nonsense mutations, seven changes affecting splicing, five frame-shift/deletions, one frame-shift/insertion and one mutation in the start codon. These results indicate that the trait is an allelic heterogeneous disorder caused by homozygous (nineteen cases) or compound heterozygous (single case) inheritance of defects. Most mutations are unique, but one, named Kayseri, is responsible for about half of the known cases. GENERAL SIGNIFICANCE Study of the defects in the ALB resulting in CAA allows the identification of "hot spot" regions and contributes to understanding the molecular mechanism underlying the trait. Such studies could also give molecular information about different aspects of ALB regulation and shed light on the regulatory mechanisms involved in the synthesis of the protein. This article is part of a Special Issue entitled Serum Albumin.
Collapse
Affiliation(s)
- Lorenzo Minchiotti
- Department of Molecular Medicine, University of Pavia, I-27100 Pavia, Italy.
| | | | | | | | | |
Collapse
|
8
|
Caridi G, Dagnino M, Lugani F, Shalev SA, Campagnoli M, Galliano M, Spiegel R, Minchiotti L. A novel mutation in the albumin gene (c.1A>C) resulting in analbuminemia. Eur J Clin Invest 2013; 43:72-8. [PMID: 23176518 DOI: 10.1111/eci.12019] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
BACKGROUND Analbuminemia (OMIM # 103600) is a rare autosomal recessive disorder manifested by the absence or severe reduction of circulating serum albumin in homozygous or compound heterozygous subjects. The trait is caused by a variety of mutations within the albumin gene. DESIGN We report here the clinical and molecular characterisation of two new cases of congenital analbuminemia diagnosed in two members of the Druze population living in a Galilean village (Northern Israel) on the basis of their low level of circulating albumin. The albumin gene was screened by single-strand conformation polymorphism and heteroduplex analysis, and the mutated region was submitted to DNA sequencing. RESULTS Both the analbuminemic subjects resulted homozygous for a previously unreported c.1 A>C transversion, for which we suggest the name Afula from the hospital where the two cases were investigated. This mutation causes the loss of the primary start codon ATG for Met1, which is replaced by a - then untranslated - triplet CTG for Leu. (p.Met1Leu). The use of an alternative downstream ATG codon would probably give rise to a completely aberrant polypeptide chain, leading to a misrouted intracellular transport and a premature degradation. CONCLUSIONS The discovery of this new ALB mutation, probably inherited from a common ancestor, sheds light on the molecular mechanism underlying the analbuminemic trait and may serve in the development of a rapid genetic test for the identification of a-symptomatic heterozygous carriers in the Druze population in the Galilee.
Collapse
Affiliation(s)
- Gianluca Caridi
- Laboratory on Pathophysiology of Uremia, Istituto Giannina Gaslini IRCCS, Genoa, Italy
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Caridi G, Dagnino M, Di Duca M, Akyuz F, Boztas G, Besisik F, Demir K, Ormeci A, Gokturk S, Cefle K, Ozturk Ş, Palanduz S, Campagnoli M, Galliano M, Minchiotti L. A novel two bases deletion in the albumin gene causes analbuminaemia in a young Turkish man. Clin Chim Acta 2012; 413:950-1. [DOI: 10.1016/j.cca.2012.01.030] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2012] [Revised: 01/25/2012] [Accepted: 01/25/2012] [Indexed: 01/14/2023]
|
10
|
Caridi G, Dagnino M, Di Duca M, Pinto H, Espinheira MDC, Guerra A, Fernandes S, Campagnoli M, Galliano M, Minchiotti L. A novel splicing mutation causes analbuminemia in a Portuguese boy. Mol Genet Metab 2012; 105:479-83. [PMID: 22227324 DOI: 10.1016/j.ymgme.2011.12.009] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2011] [Revised: 12/12/2011] [Accepted: 12/12/2011] [Indexed: 12/25/2022]
Abstract
Analbuminemia is a rare autosomal recessive disorder manifested by the absence or severe reduction of circulating serum albumin in homozygous or compound heterozygous subjects. It is an allelic heterogeneous defect, caused by a variety of mutations within the albumin gene. The analbuminemic condition was suspected in a Portuguese boy who presented with low albumin level (about 3.8 g/L) and a significant hypercholesterolemia, but with no clinical findings. The albumin gene was screened by single strand conformational polymorphism and heteroduplex analysis and submitted to direct DNA sequencing. The proband was found to be homozygous for a previously unreported G>A change at position c.1289+1, the first base of intron 10, which inactivates the strongly conserved GT dinucleotide at the 5' splice site consensus sequence of the intron. The effect of this mutation was evaluated by examining the cDNA obtained by RT-PCR from the albumin mRNA extracted from proband's leukocytes. The splicing defect results in the skipping of the preceding exon. The subsequent reading frame-shift in exon 11 produces a premature stop codon located 33 codons downstream the 5' end of the exon. This extensive cDNA alteration is responsible for the analbuminemic trait. Both parents were found to be heterozygous for the same mutation. DNA and cDNA sequence analysis established the diagnosis of congenital analbuminemia in the proband. The effects of the so far identified splice-site mutations in the albumin gene are discussed.
Collapse
Affiliation(s)
- Gianluca Caridi
- Laboratory on Pathophysiology of Uremia, Istituto Giannina Gaslini IRCCS, Genova, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Caridi G, Dagnino M, Di Duca M, Santra S, Ball S, Sulaiman RA, Campagnoli M, Galliano M, Minchiotti L. A two-base-pairs deletion in the albumin gene causes a new case of analbuminemia. Clin Chem Lab Med 2012; 50:2221-3. [DOI: 10.1515/cclm-2012-0390] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2012] [Accepted: 06/29/2012] [Indexed: 11/15/2022]
|
12
|
Human serum albumin: from bench to bedside. Mol Aspects Med 2011; 33:209-90. [PMID: 22230555 DOI: 10.1016/j.mam.2011.12.002] [Citation(s) in RCA: 1176] [Impact Index Per Article: 90.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2011] [Accepted: 12/21/2011] [Indexed: 02/07/2023]
Abstract
Human serum albumin (HSA), the most abundant protein in plasma, is a monomeric multi-domain macromolecule, representing the main determinant of plasma oncotic pressure and the main modulator of fluid distribution between body compartments. HSA displays an extraordinary ligand binding capacity, providing a depot and carrier for many endogenous and exogenous compounds. Indeed, HSA represents the main carrier for fatty acids, affects pharmacokinetics of many drugs, provides the metabolic modification of some ligands, renders potential toxins harmless, accounts for most of the anti-oxidant capacity of human plasma, and displays (pseudo-)enzymatic properties. HSA is a valuable biomarker of many diseases, including cancer, rheumatoid arthritis, ischemia, post-menopausal obesity, severe acute graft-versus-host disease, and diseases that need monitoring of the glycemic control. Moreover, HSA is widely used clinically to treat several diseases, including hypovolemia, shock, burns, surgical blood loss, trauma, hemorrhage, cardiopulmonary bypass, acute respiratory distress syndrome, hemodialysis, acute liver failure, chronic liver disease, nutrition support, resuscitation, and hypoalbuminemia. Recently, biotechnological applications of HSA, including implantable biomaterials, surgical adhesives and sealants, biochromatography, ligand trapping, and fusion proteins, have been reported. Here, genetic, biochemical, biomedical, and biotechnological aspects of HSA are reviewed.
Collapse
|
13
|
Dagnino M, Caridi G, Haenni U, Duss A, Aregger F, Campagnoli M, Galliano M, Minchiotti L. Molecular diagnosis of analbuminemia: a new case caused by a nonsense mutation in the albumin gene. Int J Mol Sci 2011; 12:7314-22. [PMID: 22174600 PMCID: PMC3233406 DOI: 10.3390/ijms12117314] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2011] [Revised: 09/15/2011] [Accepted: 10/13/2011] [Indexed: 12/25/2022] Open
Abstract
Analbuminemia is a rare autosomal recessive disorder manifested by the absence, or severe reduction, of circulating serum albumin (ALB). We report here a new case diagnosed in a 45 years old man of Southwestern Asian origin, living in Switzerland, on the basis of his low ALB concentration (0.9 g/L) in the absence of renal or gastrointestinal protein loss, or liver dysfunction. The clinical diagnosis was confirmed by a mutational analysis of the albumin (ALB) gene, carried out by single-strand conformational polymorphism (SSCP), heteroduplex analysis (HA), and DNA sequencing. This screening of the ALB gene revealed that the proband is homozygous for two mutations: the insertion of a T in a stretch of eight Ts spanning positions c.1289 + 23–c.1289 + 30 of intron 10 and a c.802 G > T transversion in exon 7. Whereas the presence of an additional T in the poly-T tract has no direct deleterious effect, the latter nonsense mutation changes the codon GAA for Glu244 to the stop codon TAA, resulting in a premature termination of the polypeptide chain. The putative protein product would have a length of only 243 amino acid residues instead of the normal 585 found in the mature serum albumin, but no evidence for the presence in serum of such a truncated polypeptide chain could be obtained by two dimensional electrophoresis and western blotting analysis.
Collapse
Affiliation(s)
- Monica Dagnino
- Laboratory on Pathophysiology of Uremia, Istituto Giannina Gaslini IRCCS, Genova 16148, Italy; E-Mails: (M.D.); (G.C.)
| | - Gianluca Caridi
- Laboratory on Pathophysiology of Uremia, Istituto Giannina Gaslini IRCCS, Genova 16148, Italy; E-Mails: (M.D.); (G.C.)
| | - Ueli Haenni
- Praxis Kreuzmatte, Kreuzstrasse 2, Postfach, 3052 Zollikofen, Switzerland
| | - Adrian Duss
- Department of Nephrology/Hypertension, Inselspital, Bern University Hospital, and University of Bern, Bern 3010, Switzerland; E-Mails: (A.D.); (F.A.)
| | - Fabienne Aregger
- Department of Nephrology/Hypertension, Inselspital, Bern University Hospital, and University of Bern, Bern 3010, Switzerland; E-Mails: (A.D.); (F.A.)
| | - Monica Campagnoli
- Department of Biochemistry “A.Castellani”, University of Pavia, Pavia 27100, Italy; E-Mails: (M.C.); (M.G.)
| | - Monica Galliano
- Department of Biochemistry “A.Castellani”, University of Pavia, Pavia 27100, Italy; E-Mails: (M.C.); (M.G.)
| | - Lorenzo Minchiotti
- Department of Biochemistry “A.Castellani”, University of Pavia, Pavia 27100, Italy; E-Mails: (M.C.); (M.G.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +39-0382-987724; Fax: +39-0382-423108
| |
Collapse
|